Communiqués Anagenics Limited

Actions

Marché Fermé - Australian S.E. Autres places de cotation 07:46:47 18/07/2024			Varia. 5j.	Varia. 1 janv.
0,008 ^AUD	0,00 %		0,00 %	-57,89 %

24/05	Anagenics signe un accord de licence pour l'anticorps Midkine avec Roquefort Therapeutics	MT
08/03	Anagenics nomme un PDG	MT

Anagenics : FY2022 Annual Report	05/12/22	PU
Anagenics : Appendix 4C and Quarterly Activity Report	26/07/22	PU
Anagenics : Appendix 4C and Quarterly Activity Report	28/04/22	PU
Cellmid : AGM Presentation to Shareholders	09/12/21	PU
Cellmid : Alopecia Patent allowed in Europe	02/04/19	PU
Cellmid : Investor Newsletter March 2019	26/03/19	PU
Cellmid : Appendix 4D, Half Year Accounts and Strategy Update	21/02/19	PU
Cellmid : Significant New Findings Published On MIDKINE	07/02/19	PU
Cellmid : Appendix 4C and Notes to Appendix 4C	23/01/19	PU
Cellmid : Investor Newsletter - December 2018_Not announced on ASX	21/12/18	PU
Cellmid : CDY- Cellmid Expects Record Sales in Q2 FY2019	12/12/18	PU
Cellmid : CDY - Cellmid Appoints Exclusive New Zealand Distributor	19/11/18	PU
Cellmid : CDY - Change of Directors Interest Notice - Halasz	13/11/18	PU
Cellmid : CDY - Change of Directors Interest Notice - Eck	13/11/18	PU
Cellmid : Change of Director's Interest Notice_Bruce Gordon	25/09/18	PU
Nature Publication Identifies Cellmid Limited's Midkine as Important Target	03/07/17	AW
Cellmid : Cellmids FGF5 Inhibitor Clinical Study Published	02/03/17	PU
Cellmid : to Refinance R&D Loan Facility	01/03/17	PU
Cellmid : Appendix 4D and Half Year Accounts	28/02/17	PU
Cellmid : European Midkine Alopecia Patent Allowed	07/02/17	PU

Aucun résultat pour cette recherche